• Immunofluorescence analysis of PC-12 cells using DNAJC4 Rabbit polyclonal antibody (STJ11105234) at dilution of 1:20 (40x lens). Secondary antibody: Cy3 Goat Anti-Rabbit IgG (H+L) at 1:500 dilution. Blue: DAPI for nuclear staining.
  • Immunofluorescence analysis of HepG2 cells using DNAJC4 Rabbit polyclonal antibody (STJ11105234) at dilution of 1:20 (40x lens). Secondary antibody: Cy3 Goat Anti-Rabbit IgG (H+L) at 1:500 dilution. Blue: DAPI for nuclear staining.

Anti-DNAJC4 antibody (35-100) (STJ11105234)

SKU:
STJ11105234

Current Stock:
Host: Rabbit
Applications: IF
Reactivity: Human/Rat
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Rabbit polyclonal antibody anti-Dnaj Homolog Subfamily C Member 4 (35-100) is suitable for use in Immunofluorescence research applications.
Clonality: Polyclonal
Conjugation: Unconjugated
Isotype: IgG
Formulation: PBS with 0.05% Proclin300, 50% Glycerol, pH7.3.
Purification: Affinity purification
Dilution Range: IF/ICC 1:50-1:200
Storage Instruction: Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles.
Gene Symbol: DNAJC4
Gene ID: 3338
Uniprot ID: DNJC4_HUMAN
Immunogen Region: 35-100
Immunogen: Recombinant fusion protein containing a sequence corresponding to amino acids 35-100 of human DNAJC4 (NP_005519.2).
Immunogen Sequence: YYELLGVHPGASTEEVKRAF FSKSKELHPDRDPGNPSLHS RFVELSEAYRVLSREQSRRS YDDQLR
Protein Name Dnaj Homolog Subfamily C Member 4
Dnaj-Like Protein Hspf2
Multiple Endocrine Neoplasia Type 1 Candidate Protein Number 18
Cellular Localisation Membrane
Single-Pass Membrane Protein
Alternative Antibody Names Anti-Dnaj Homolog Subfamily C Member 4 antibody
Anti-Dnaj-Like Protein Hspf2 antibody
Anti-Multiple Endocrine Neoplasia Type 1 Candidate Protein Number 18 antibody
Anti-DNAJC4 antibody
Anti-HSPF2 antibody
Anti-MCG18 antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance